Does anyone know why it states in the Bell Potter report that "at an annual reimbursement of $100,000 per patient, Rett Syndrome wouldrepresent a US$1.6bn market and Fragile X would represent a US$7bn market in the US alone", while earlier in their report they state that peak worldwide annual sales will be 500m and 700m for Rett and Fragile X?
Is it something to do with licensing?
- Forums
- ASX - By Stock
- NEU
- Ann: Investor Presentation, 8 January 2015
Ann: Investor Presentation, 8 January 2015, page-46
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.87 |
Change
0.320(1.56%) |
Mkt cap ! $2.667B |
Open | High | Low | Value | Volume |
$20.86 | $21.29 | $20.84 | $3.796M | 180.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $20.85 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.87 | 844 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 20.850 |
1 | 837 | 20.840 |
4 | 1973 | 20.800 |
1 | 2432 | 20.780 |
3 | 2561 | 20.760 |
Price($) | Vol. | No. |
---|---|---|
20.870 | 844 | 1 |
20.890 | 2740 | 1 |
20.900 | 2212 | 3 |
20.950 | 250 | 1 |
20.990 | 284 | 1 |
Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online